Atypical ductal hyperplasia: breast DCE-MRI can be used to reduce unnecessary open surgical excision

• Published in: European radiology 2020-07, Vol.30 (7), p.4069-4081
• Main Authors: Bertani, Valeria, Urbani, Martina, La Grassa, Manuela, Balestreri, Luca, Berger, Nicole, Frauenfelder, Thomas, Boss, Andreas, Marcon, Magda
• Format: Article
• Language: English
• Subjects: Biopsy; Breast; Breast cancer; Cancer; Diagnosis; Diagnostic Radiology; Diagnostic systems; Hyperplasia; Imaging; Internal Medicine; Interventional Radiology; Invasiveness; Lesions; Magnetic resonance imaging; Malignancy; Mammography; Medical imaging; Medicine; Medicine & Public Health; Neuroradiology; Patients; Performance evaluation; Radiology; Surgery; Ultrasound; Vacuum
• ISSN: 0938-7994; 1432-1084
• DOI: 10.1007/s00330-020-06701-3

Purpose To evaluate the diagnostic performance of dynamic contrast-enhanced (DCE)–MRI in predicting malignancy after percutaneous biopsy diagnosis of atypical ductal hyperplasia (ADH). Methods and materials In this retrospective study, 68 lesions (66 women) with percutaneous biopsy diagnosis of ADH and pre-operative breast DCE-MRI performed between January 2016 and December 2017 were included. Two radiologists reviewed in consensus mammography, ultrasound, and MR images. The final diagnosis after surgical excision was used as standard of reference. Clinical and imaging features were compared in patients with and without upgrade to malignancy after surgery. The diagnostic performance of DCE-MRI in predicting malignant upgrade was evaluated. Results A 9-gauge vacuum-assisted biopsy was performed in 40 (58.8%) cases and a 14-gauge core needle biopsy in 28 (41.2%) cases. Upgrade to malignancy was observed in 17/68 (25%) lesions, including 4/17 (23.5%) cases of invasive cancer and 13/17 (76.5%) cases of ductal carcinoma in situ (DCIS). In 16/17 (94.1%) malignant and 20/51 (39.2%) benign lesions, a suspicious enhancement could be recognized in DCE-MRI. The malignant lesion without suspicious enhancement was a low-grade DCIS (4 mm size). Sensitivity, specificity, positive predictive value, and negative predictive value of DCE-MRI on predicting malignancy were respectively 94.1%, 60.7%, 44.4%, and 96.8%. No other clinical or imaging features were significantly different in patients with and without upgrade to malignancy. Conclusion After a percutaneous biopsy diagnosis of ADH, malignancy can be ruled out in most of the cases, if no suspicious enhancement is present in the biopsy area at DCE-MRI. Breast DCE-MRI may be used to avoid surgery in more than half of the patients with final benign diagnosis. Key Points • Breast DCE-MRI can safely rule out malignancy if no suspicious enhancement is present in the biopsy area after a percutaneous biopsy diagnosis of ADH. • All cases of upgrade to high-grade DCIS and invasive cancers can be identified at breast DCE-MRI after a percutaneous biopsy diagnosis of ADH. • Breast DCE-MRI may be used to avoid surgery in more than half of the patients with final benign diagnosis.